News

Evaluation of ex vivo drug combination optimization platform in recurrent high grade astrocytic glioma: An interventional, non-randomized, open-label trial protocol

Dr Toh Tan Boon’s team is excited to share their latest clinical trial protocol in PLOS ONE, “Evaluation of ex vivo drug combination optimization platform in recurrent high grade astrocytic glioma: An interventional, non-randomized, open-label trial protocol”.

Read More: Evaluation of ex vivo drug combination optimization platform in recurrent high grade astrocytic glioma: An interventional, non-randomized, open-label trial protocol – PLOS ONE

view MORE related

News

2026
New insights into epigenetic suppression in liver cancer
More Details >
2026
What a zebrafish can teach us about alcohol addiction
More Details >
2026
Experimental & Molecular Medicine – The functional imperative in high-grade glioma
More Details >
get in touch and

Contact Us

For inquiries pertaining to our R&D Programs, please contact Khew Si Ying at khewsiying@nus.edu.sg